• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

The Week Ahead, Markets Haven't Been Wrong, Closer to a Vaccine? Watching J&J

The equity market recovery is just as sloppy in performance as the economy itself.
By STEPHEN GUILFOYLE
Aug 24, 2020 | 07:19 AM EDT
Stocks quotes in this article: AAPL, TSLA, AMZN, XLK, AZN, PFE, BNTX, JNJ, PANW

Monday morning. Where do we stand going into this new week? Foreign markets and U.S. equity index futures markets have traded higher overnight. We'll get to that shortly. Markets measured at the headline level have continued to make new highs, after a series of stutter steps, all while leadership has continued to narrow. The talk over the weekend, or at least the early part of the weekend, had been all about record highs for the Nasdaq Composite and S&P 500 driven "generally" by mega-cap tech names, but even that word "generally" is a little broad. The markets have been driven really by a sudden (sudden as in weeks, not minutes) realization that especially Apple (AAPL) and Tesla (TSLA) had been somehow under-owned at the professional level. Makes some sense, with both of those names in particular splitting shares, as that does at least begin to address the market-wide issue that scarcity of equity had become. Who's next became the question many asked? Amazon (AMZN) would be my guess. Still just a guess, and I am long that name. You don't have to have a ton of education to speculate.

It is true though that mega cap, mostly tech names have only been able to drag a minority of individual issues with them to the upside. This does not signal coming weakness. This does not signal anything in my opinion. It just means that as certain names grow in market capitalization they then become more significant in leading the performance of that given headline market index, as that's how our most followed indices are weighted. Underperforming your benchmark this year? I know that does not feel very good, but from an ego feeding perspective, you may be more diversified than that benchmark is itself. You might be beating the market without beating your benchmark. Got me?

On Friday, 220 of the S&P 500's constituent member issues closed higher. That was better than Thursday. Both days were officially "up" days. In fact, at the New York Stock Exchange, losers beat winners on Friday almost two to one, while declining volume decisively beat advancing volume. In fact, just about the only positive takeaway I have after scanning the NYSE's data for the day, would be that trading volume itself decreased ever so slightly on what without knowing better, looks like a "down" day. Same story up in midtown. At the Nasdaq Market site, losers also beat winners almost 2 to 1. Declining volume also handily beat advancing volume. Trading volume at the Nasdaq (more optimistically?) dropped off more dramatically from Thursday to Friday at the Nasdaq than it did at 11 Wall Street.

Economic Perspective

It has been spoken of and written on often across the realm not since this awful coronavirus first started having a negative impact on all of our lives, but since the aggressive recovery in equity markets became quite evidently more robust, particularly in June and beyond. We have harped on the fact that historical valuation metrics were quite useless in a never seen before financial environment. Still, you will read here and there, quite educated, and quite intelligent (and well known) financial pundits who do not understand how this works. Such is life. Either they do not understand, or they have something to sell.

The fact is that at the headline, equity market performance is not reflective of the uneven, both in depth and velocity of the economic rebound in the U.S. Beyond those headline indices, however, the equity market recovery is just as sloppy in performance as the economy itself. The Dow Transports have gained back quite a bit, though still underperform the two large cap indices that most follow closely. Sure, that index is narrow, and highly specialized. However, the economy goes nowhere without the transports, nor the banks. Yeah, how are the banks doing? Better not look. Okay, go ahead, the group is a mess. Now broaden the scope, but downsize in market cap. The S&P 400 (mid-caps), as well as the small cap indices (Russell 2000, and S&P 600)? Survey says: BZZZ !! Still better than the banks. The banks can not recover until investors know that their debtors are in okay shape. Understand? Then, once that condition is satisfied, the group is valued based on net interest margin... even if they invent a hundred other ways to profit. Now, you know why nobody paying attention is overweight the banks. Just a fact of life. For now. Everything changes. Sometimes you don't see it coming.

Understand This

The markets have not been wrong. The narrowing market success is precisely representative of narrowing economic success. Just last week, every one of you saw some red hot housing data for July hit the tape. You also saw key regional manufacturing surveys represent businesses that continued to grow in August, but appear to have taken a sideways bent. Then there was the employment picture. An unwelcome rebound in claims for jobless benefits. Can a less than confident household drive consumption?

Last week (using select sector SPDR ETFs as proxies), the Tech sector (XLK) ran more than 4%, easily outperforming measures that single out either semiconductors or software. AAPL screamed 8.2% higher over five days. Apple is considered hardware, though investors value the brand as a software subscription type business with a hardware driven, captive customer base. Consumer Discretionaries finished in second place for the week at +1.8%. Autos, yes autos easily led once that performance is broken out by industry. Tesla gained more than 24% for the week.

This is not rocket science. What this is... is what uncertainty looks like. Understand this now, so you don't get shaken out at the time. At a market cap of $2T+, when "they" do take profits in AAPL, the Dow, the S&P 500, and the Nasdaq Composite will all sell off, perhaps sharply, even if broader equity markets have a good day. Bear in mind that while yes, fiscal policy has provided short-term support to the economy, and the monetary policy has funded that effort at little cost while ensuring that the plumbing works. While this effort had been grand in scale, it has not been able to, and can not lift all boats equally, or even lift all boats. There will be more financial casualties.

Emergency Use Authorization

We did mention above that markets were stronger overnight. President Trump made an announcement on Sunday evening. The Food and Drug Administration had authorized use of convalescent plasma taken from recovered Covid-19 patients as treatment for those seriously ill with the infection. What this does is waive some regulatory requirements involved in making use of certain medical products that are not yet fully FDA approved. Limited studies show that hospitalized patients not requiring ventilation may show as much as a 35% improvement in survivability 30 days after receiving the plasma, if received within three days of diagnosis. No magic wand. Just positive development.

At almost the same time, the Financial Times ran a story suggesting that the Trump administration might be considering fast-tracking the Covid-19 vaccine being collaborated on in the UK by AstraZeneca (AZN) and Oxford University based upon a somewhat small trial if successful. That study included 10,000 volunteers, whereas the standard set in this country calls for 30,000. There has been no official comment made regarding this possibility as far as I can tell. You did see the news on Friday that Pfiizer (PFE) and BioNTech (BNTX) could have a vaccine ready for regulatory review as soon as October. Financial markets are starting to feel like something is close.

Positioning

Short interest continues to drop. According to data published at Goldman Sachs, which I read in the Financial Times, such interest as a proportion of market cap for the median stock in the S&P 500 has fallen to 1.8%. This would be the smallest this percentage has been since Goldman started tracking this data in 2004. The 15 year average runs at about 2.4%.

Breakout?

Maybe. Johnson & Johnson (JNJ) , another vaccine name, the one looking forward to a global trial including 60,000 volunteers, may be on the verge of a technical break-out.

Readers will see the blue cup created last spring. There is really no handle there, and there was no breakout created at that time. Since, we have a rather shallow "saucer" formed in orange that lasted from May into July. This saucer has created a handle, with a pivot point just below $152. That spot was taken on Friday. Can it hold? Will it hold? I have increased my target price for JNJ to $184 from $174 based on the new pivot. At the same time, I am increasing my panic point from $133 to $143.

Economics (All Times Eastern)

No significant domestic macroeconomic data scheduled.

The Fed (All Times Eastern)

No Public Appearances Scheduled.

Today's Earnings Highlights (Consensus EPS Expectations)

After the Close: (PANW) (1.39)

(Apple, Amazon, and Johnson & Johnson are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long AMZN, PFE, JNJ equity.

TAGS: Economy | Investing | Markets | Small Cap | Stocks | Technical Analysis | Trading | Banking | Coronavirus

More from Investing

The 10 Personality Traits of Successful Traders and Investors

James "Rev Shark" DePorre
Jun 25, 2022 10:00 AM EDT

Superior market players share these characteristics in their emotional makeup.

Does the Big Bounce Mean More to Come? Let's See What Drove the Move

James "Rev Shark" DePorre
Jun 24, 2022 4:42 PM EDT

Much of the rally can be attributed to structural reasons, not fundamentals, technicals, or even macro ones.

MongoDB Is Poised for a Rally

Bruce Kamich
Jun 24, 2022 2:15 PM EDT

Here's our initial upside price target for MDB which provides a general purpose database platform.

See That Down the Road? It's the Big 'Green' Bubble, Ready to Pop

Jim Collins
Jun 24, 2022 1:30 PM EDT

Environmental, social, and corporate governance has created a monster and gullible investors should hit the brakes on their EVs and run from the Washington technocrats while they have the chance.

Treat Becton, Dickinson and Company With Care

Bruce Kamich
Jun 24, 2022 1:25 PM EDT

BDX gets an upgrade, but are the charts healthy enough to recommend?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login